Eurocine Vaccines contracts Artemis Bioservices as CRO
Eurocine Vaccines AB (publ) ("Eurocine Vaccines" or "the Company") announces today that the Company has contracted Artemis Bioservices B.V. (”Artemis Bioservices”) as a CRO (Contract Research Organization) for the upcoming preclinical studies with its mRNA-based vaccine candidate against Herpes Simplex Virus type 2 (HSV-2). The first preclinical study is planned to start as soon as sufficient funding has been secured through the ongoing unit issue, and to be conducted during the first half of 2024.Eurocine Vaccines is a development company that bridges the gap between innovations and market